Aidence provides AI-powered clinical applications for lung cancer management, specifically through its CE-certified Veye Lung Nodules solution, which automates the detection and quantification of lung nodules in chest CT scans. This technology enhances the efficiency and accuracy of radiology workflows, facilitating standardized reporting and improving the quality of cancer care in routine clinical practice.

AmbAgon Therapeutics develops targeted cancer molecule therapeutics that utilize specific molecular pathways to inhibit tumor growth. The company focuses on providing effective treatment options for patients with various types of cancer, addressing the need for more precise and less toxic therapies.

Anavo Therapeutics utilizes its IGNITE platform to develop allosteric modulators targeting phosphatases, a class of enzymes that have been largely overlooked in drug discovery despite their critical role in regulating cellular signaling pathways. By focusing on phosphatase biology, Anavo aims to create first-in-class therapeutics for various diseases, addressing the significant gap in approved drugs that specifically target these enzymes.

Baserow is an open-source, self-hosted database platform that enables teams to manage and visualize data collaboratively without the constraints of traditional spreadsheets. It eliminates the need for costly software subscriptions and IT overhead, providing a scalable solution that integrates with existing tools through an API-first approach.

Cardior Pharmaceuticals develops non-coding RNA-based therapeutics, specifically CDR132L, to reverse adverse cardiac remodeling in heart failure patients following myocardial infarction. Their approach targets the underlying mechanisms of heart disease, aiming to restore normal cellular functions and improve patient outcomes.

Castor provides a cloud-based clinical data platform that integrates electronic data capture (EDC), electronic patient-reported outcomes (ePRO), and electronic consent (eConsent) to facilitate decentralized clinical trials. This platform enables researchers to efficiently collect, manage, and analyze data from multiple sources while ensuring compliance with regulatory standards, ultimately reducing the time and complexity of clinical trial processes.

ChannelEngine is a marketplace integration and management platform that connects brands and retailers to over 950 global marketplaces, enabling streamlined operations through automated product syndication, order management, and pricing tools. The platform addresses the complexity of managing multi-channel sales by providing centralized control over inventory, content, and analytics, ultimately driving profitable growth for sellers and vendors.

Corporis Medical develops the Mediclose System, a single-use suturing device designed for percutaneous suturing of port-site fascia wounds after laparoscopic surgery, and the Laprixa System, the smallest tissue blood pressure measurement device for assessing wound healing capacity. These devices enhance outcomes in minimally invasive surgeries by providing precise suturing solutions and objective, quantitative assessments of tissue healing.

Draupnir Bio is developing oral small molecule degraders that utilize lysosomal machinery to target and eliminate extracellular pathogenic proteins, addressing the need for effective treatments in cholesterol metabolism and cardiovascular disease. Their proprietary technology platform aims to revolutionize targeted protein degradation by specifically targeting lysosome receptors, potentially reducing the risk of heart-related complications.

GeoPhy utilizes data science to analyze hyperlocal real estate data, providing insights into market opportunities and risk assessments for properties. Their platform enables users to quantify potential investments and prioritize deals based on specific market criteria, enhancing decision-making in a dynamic real estate landscape.

The startup offers a web‑based DevSecOps platform that combines Git source control, automated CI/CD pipelines, and integrated security scanning in a single interface. AI‑driven code suggestions and contextual chat help developers fix vulnerabilities as they code, while built‑in compliance reporting and value‑stream analytics provide continuous auditability and performance insights. The solution enables enterprise development teams to ship software faster without sacrificing security.

Happeo is an AI-powered intranet platform that centralizes knowledge management and internal communication, enabling teams to access trusted information and collaborate effectively. It addresses the inefficiencies of fragmented communication and knowledge silos, enhancing productivity and alignment across organizations.

IB is an insurance management app that digitizes and consolidates users' insurance policies, allowing for easy access and sharing among family members. The platform identifies potential claims based on user-reported incidents, helping to prevent missed opportunities for insurance payouts.

iOnctura develops precision oral small molecules targeting neglected and hard-to-treat cancers by modulating key signaling pathways, including allosteric modulation of PI3Kδ and inhibition of autotaxin. Their therapies aim to reduce the severe side effects associated with conventional treatments, thereby improving patient healthspan and overall survival.

NMD Pharma develops small‑molecule inhibitors of the skeletal‑muscle‑specific ClC‑1 chloride ion channel to directly improve muscle excitability, strength, and fatigue resistance. Leveraging a proprietary electrophysiology platform, the company advances candidates for rare neuromuscular disorders such as myasthenia gravis, spinal muscular atrophy, Charcot‑Marie‑Tooth disease, and age‑related sarcopenia.

Onward has developed the ARCEX System, a non-invasive spinal cord stimulation device that delivers electrical pulses to the cervical spinal cord through surface electrodes to enhance hand sensation and strength in individuals with chronic cervical spinal cord injuries. This technology aims to improve upper limb function and quality of life for patients, with clinical studies showing significant improvements in strength and sensory scores.

Precirix is developing precision radiopharmaceuticals that utilize camelid single-domain antibodies labeled with radiometals to target Fibroblast Activation Protein (FAP) in cancer treatment. This approach aims to provide a first-in-class alpha-emitting targeted radiotherapy for a broad range of tumors, addressing the need for more effective cancer therapies.

Provable Labs provides the Aurora platform—a cloud‑native suite that combines Aurora Marketplace™ and Aurora Trade Manager™ to automate securities lending across front, middle, and back‑office functions. The platform offers real‑time order matching, end‑to‑end trade‑life‑cycle automation, and integrated connectivity to clearing houses and custodians via open FIX, REST, and gRPC APIs, reducing manual breaks and counterparty risk for securities lending desks, prime brokers, and asset managers.

Quantum Motion is developing a scalable array of qubits using CMOS-compatible silicon technology, enabling the construction of a universal quantum computer. This approach addresses the limitations of current quantum computing architectures by facilitating robust error correction and miniaturization, allowing for practical applications in fields such as chemistry, medicine, and artificial intelligence.

The startup develops precision therapeutics and diagnostic tools targeting genetically validated alterations in amyotrophic lateral sclerosis and other neurodegenerative diseases. Its proprietary platforms enable the design of drugs that can halt disease progression and improve patient outcomes through direct intervention on genetic factors.

Rani Therapeutics has developed the RaniPill platform, which enables the oral delivery of biologics, including proteins and antibodies, with bioavailability comparable to subcutaneous injections. This technology addresses the challenges of painful and inconvenient injections for patients requiring chronic biologic treatments, improving compliance and quality of life.

Remote is a global HR platform that enables companies to hire, manage, and pay employees and contractors across multiple countries without the need for local entities, ensuring compliance with local labor laws. By streamlining payroll, HRIS, and contractor management into a single platform, Remote reduces administrative burdens and accelerates the hiring process, allowing businesses to scale efficiently.

Salvia BioElectronics develops a bioelectronic therapy for individuals suffering from chronic migraine and cluster headache. Their MySalvia Therapy utilizes an ultra-thin implant activated by a wearable device to provide drug-free neuromodulation relief. This technology aims to allow millions of people to manage their neurological pain without interruption to daily life.

Scenic Biotech develops genomics and immunotherapy technologies to identify and utilize genetic suppressors for therapeutic applications. Their platform targets disease pathways in neuro- and metabolic disorders, enabling the creation of disease-modifying therapies that offer new treatment options for patients.